Africa Biosimilar Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026

The regional research report on the Africa biosimilar market is a customer intelligence and competitive study of the Africa market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Africa market. Also, factors that are driving and restraining the biosimilar market are highlighted in the study. This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market. Additionally, this report provides readers with market insights and detailed analysis of market segments to possible mi

Africa biosimilar market was valued 267.1 million in 2019 and is projected to reach USD 1823.5 million by 2026. The Africa biosimilar market is expected to grow at a CAGR of 32.00% between 2020 and 2026 in terms of value. The African market for biosimilars is in its infancy, but due to the population size and the high cost of biological drugs, the potential is immense. It is anticipated that biosimilars can allow more access to care for patients through cost savings.  

Market giants in the global biosimilar industry are using several strategies and are adapting their business models to gain traction in the African continent. Several players are entering into a collaboration with local players, which in turn will drive the growth of the biosimilar market in Africa. Moreover, the disease burden of cancer is growing in African countries, driving the demand for oncology biosimilars in Africa. On the other hand, the biosimilar regulatory framework is unclear and inconsistent in several African countries currently.   

However, as legislation is expected to be adopted in Algeria, Morocco and Tunisia within the next few months with respect to the WHO, EMA and FDA guidelines in terms of biosimilarity, consistency, effectiveness, and safety standards, it is expected to bring several growths opportunities for several players in the African markets. Moreover, with the increasing transformation in the overall pharmaceutical landscape towards biologics due to patent expiration, biosimilars offer an enormous opportunity for innovative biotech and generic companies operating in the African markets as well as for the ones trying to enter the market.

Segments Covered

The report on Africa biosimilar market provides a detailed analysis of segments in the market based on the product, and application. 

Segmentation Based on Product 

·         Human Growth Hormones

·         Monoclonal Antibodies

·         Insulin

·         Peptides

·         Erythropoietin

·         Other Products 

Segmentation Based on Application           

·         Oncology

·         Chronic and Autoimmune Diseases

·         Growth Hormone Deficiency

·         Infectious Diseases

·        Other Applications 

Highlights of the Report 

The report provides detailed insights into:

 1) Demand and supply conditions of the biosimilar market

 2) Factor affecting the biosimilar market in the short run and the long run

 3) The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, and technological factors

 4) Key trends and future prospects

 5) Leading companies operating in the biosimilar market and their competitive position in Africa

 6) The dealers/distributors profiles provide basic information of top 10 dealers & distributors operating in (Africa) biosimilar market

 7) IGR Matrix: to position the product types

 8) Market estimates up to 2026

 The report answers questions such as:

 1) What is the market size of biosimilar market in Africa?

 2) What are the factors that affect the growth in biosimilar market over the forecast period?

 3) What is the competitive position in Africa biosimilar market?

 4) What are the opportunities in Africa biosimilar market?

 5) What are the modes of entering Africa biosimilar market?